Home Articles List Article Information
Medical Journal of Viral Hepatitis
Journal Archive
Volume Volume 8.2 (2024)
Volume Volume 8.1 (2024)
Volume Volume 7.3 (2023)
Volume Volume 7.2 (2023)
Volume Volume 7.1 (2022)
Volume Volume 6.3 (2022)
Volume Volume 6.2 (2022)
Volume Volume 6.1 (2021)
Volume Volume 5.3 (2021)
Volume Volume 5.2 (2021)
Volume Volume 5.1 (2020)
Volume Volume 4.2 (2020)
Volume Volume 4.1 (2019)
Volume Volume 3.2 (2019)
Volume Volume 3.1 (2018)
Volume Volume 2.2 (2018)
Volume Volume 2.1 (2016)
Volume Volume 1.2 (2016)
Volume Volume 1.1 (2015)
Anyovi, F., Sabi, A., Amekoudi, Y., Tsevi, M., Soliman, R., Charles, P., Karou, S., Simpore, J., Gamal, S. (2021). Seroepidemiology and risk factor of hepatitis B and C virus infections in hemodialysis patients in Lomé, Togo.. Medical Journal of Viral Hepatitis, 5.3(3), 22-26. doi: 10.21608/mjvh.2021.193441
Folly Anyovi; Akomola k. Sabi; Yoan y. Amekoudi; Mawufemo C. Tsevi; Reham Soliman; Pardessus Charles; Simplice Karou; Jacques Simpore; Shiha Gamal. "Seroepidemiology and risk factor of hepatitis B and C virus infections in hemodialysis patients in Lomé, Togo.". Medical Journal of Viral Hepatitis, 5.3, 3, 2021, 22-26. doi: 10.21608/mjvh.2021.193441
Anyovi, F., Sabi, A., Amekoudi, Y., Tsevi, M., Soliman, R., Charles, P., Karou, S., Simpore, J., Gamal, S. (2021). 'Seroepidemiology and risk factor of hepatitis B and C virus infections in hemodialysis patients in Lomé, Togo.', Medical Journal of Viral Hepatitis, 5.3(3), pp. 22-26. doi: 10.21608/mjvh.2021.193441
Anyovi, F., Sabi, A., Amekoudi, Y., Tsevi, M., Soliman, R., Charles, P., Karou, S., Simpore, J., Gamal, S. Seroepidemiology and risk factor of hepatitis B and C virus infections in hemodialysis patients in Lomé, Togo.. Medical Journal of Viral Hepatitis, 2021; 5.3(3): 22-26. doi: 10.21608/mjvh.2021.193441

Seroepidemiology and risk factor of hepatitis B and C virus infections in hemodialysis patients in Lomé, Togo.

Article 4, Volume 5.3, Issue 3, September 2021, Page 22-26  XML PDF (158.29 K)
Document Type: Original article
DOI: 10.21608/mjvh.2021.193441
View on SCiNiTO View on SCiNiTO
Authors
Folly Anyovi email 1, 2; Akomola k. Sabi3, 4; Yoan y. Amekoudi4; Mawufemo C. Tsevi4; Reham Soliman5, 6; Pardessus Charles7; Simplice Karou8; Jacques Simpore1, 2; Shiha Gamal9, 10
1Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR-SVT, Joseph KI-ZERBO University, Ouagadougou, Burkina Faso.
2Pietro Annigoni Biomolecular Research Center (CERBA), 01 BP 364 Ouagadougou 01, Burkina Faso.
3Ecole Supérieure des Techniques Biologiques et Alimentaires (ESTBA), Université de Lomé-Togo.
4CHU Sylvanus Olympio, Service de Néphrologie-Hemodialyse,
5Egyptian Liver Research Institute and Hospital (ELRIAH), Sherbin, El Mansoura, Egypt
6Tropical Medicine Department, Faculty of Medicine, Port Said University, Egypt
7Faculté des sciences de la Santé, Université de Lomé.
8Ecole Supérieure des Techniques Biologiques et Alimentaires (ESTBA), Université de Lomé-Togo
9Internal Medicine dept., Mansoura Univ., Egypt
10Egyptian Liver Research Institute and Hospital (ELRIH), Sherbin, El-Mansoura, Egypt.
Abstract
Background: The prevalence of hepatitis B surface antigen (HBsAg)  and anti-HCV infection  (anti-HCV) among hemodialysis patients (HD) varies from country to country and from one center to another. This cross-sectional study  was conducted to investigate seroprevalence and associated risk factors for HBsAg and anti-HCV markers among hemodialysis patients in S.O. CHU in Lomé.
Materials and methods: Structured questionnaires were used to obtain socio-demographic data and sera  were tested for HBsAg and anti-HCV among End Stage Renal Disease (ESRD) patients undergoing hemodialysis in S.O. CHU in Lomé. Results: Out of 75 patients enrolled in the study, HBsAg and anti-HCV were detected in 6 (8%) and 11 (14.7%) patients respectively. Anti-HCV and HBsAg seropositivity were not associated  with the hemodialysis session (p = 0.88) and (p = 0.91) respectively. Furthermore, Univariate analysis showed that, sex, tatoo before dialysis and a history of surgery were not a significant risk factors for HBsAg and HCV seropositivity. The follow-up of the ALT in the both patients (HCV and HBsAg) showed very high significant variation (p = 0.000) and (p = 0.02) respectively. Conclusion: Prevalence of HBsAg and anti-HCV in hemodialysis patients seems low in Lomé. It is recommended to check the patients for HBsAg and anti-HCV before admission to the centers.
Keywords
Seroepidemiology; HBV; HCV; hemodialysis; Togo
Statistics
Article View: 197
PDF Download: 384